A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease

NCT07078955 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

99

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Disease (DED)
Keratoconjunctivitis Sicca

Interventions

DRUG: BRM421 Ophthalmic Solution, 0.03%
DRUG: Artificial Tear
DRUG: BRM421 Ophthalmic Solution, 0.06%

Sponsor

BRIM Biotechnology Inc.